Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Feb;4(1):277-82.
doi: 10.2147/ndt.s2351.

Preliminary effects of pagoclone, a partial GABA(A) agonist, on neuropsychological performance

Angela F Caveney  1 , Bruno Giordani, George M Haig
Affiliations

Preliminary effects of pagoclone, a partial GABA(A) agonist, on neuropsychological performance

Angela F Caveney et al. Neuropsychiatr Dis Treat. 2008 Feb.

Abstract

Pagoclone is a novel cyclopyrrolone that acts as a partial GABA(A) receptor agonist. Preclinical studies suggest that pagoclone may have clinical utility as an anxiolytic agent, as well as a reduced incidence of side-effects. The present study was conducted to determine whether pagoclone would affect healthy individuals' performances on neuropsychological measures as a function of dose within the projected therapeutic range. Twelve healthy adult subjects were randomly assigned to dosage groups in a 3-way crossover study. Participants were administered neuropsychological measures six hours following dosing on Day 1 and Day 6 of administration of the drug. Dose effects were noted on measures of alertness, learning, and memory and movement time. Significant effects were also noted on measures of alertness, learning and memory, information processing and psychomotor speed. Overall, the results of this small, preliminary study do not support a finding of behavioral toxicity for these doses of pagoclone. Rather, a pattern was found of transient and mild negative effects on learning and memory scores at the highest dose administered, though these changes were small and no longer evident by the sixth day of use.

Keywords: cyclopyrrolone; generalized anxiety disorder; memory; neuropsychological; pagoclone.

PubMed Disclaimer

References

    1. Allain H, Patat A, Lieury, et al. Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur Psychiatry. 1995;10:S129–S135. - PubMed
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. IV-TR. Washington, DC: American Psychiatric Association; 2000.
    1. Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs. 2005;14:601–18. - PubMed
    1. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning 5. Neurology. 1974;24:1019–25. - PubMed
    1. Curran HV. Tranquillising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol. 1986;23:179–213. - PubMed